Literature DB >> 21641395

Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease.

Klemen Strle1, Kathryn L Jones, Elise E Drouin, Xin Li, Allen C Steere.   

Abstract

Evidence is emerging for differential pathogenicity among Borrelia burgdorferi genotypes in the United States. By using two linked genotyping systems, ribosomal RNA intergenic spacer type (RST) and outer surface protein C (OspC), we studied the inflammatory potential of B. burgdorferi genotypes in cells and patients with erythema migrans or Lyme arthritis. When macrophages were stimulated with 10 isolates of each RST1, RST2, or RST3 strain, RST1 (OspC type A)-stimulated cells expressed significantly higher levels of IL-6, IL-8, chemokine ligand (CCL) 3, CCL4, tumor necrosis factor, and IL-1β, factors associated with innate immune responses. In peripheral blood mononuclear cells, RST1 strains again stimulated significantly higher levels of these mediators. Moreover, compared with RST2, RST1 isolates induced significantly more interferon (IFN)-α, IFN-γ, and CXCL10, which are needed for adaptive immune responses; however, OspC type I (RST3) approached RST1 (OspC type A) in stimulating these adaptive immune mediators. Similarly, serum samples from patients with erythema migrans who were infected with the RST1 genotype had significantly higher levels of almost all of these mediators, including exceptionally high levels of IFN-γ-inducible chemokines, CCL2, CXCL9, and CXCL10; and this pronounced inflammatory response was associated with more symptomatic infection. Differences among genotypes were not as great in patients with Lyme arthritis, but those infected with RST1 strains more often had antibiotic-refractory arthritis. Thus, the B. burgdorferi RST1 (OspC type A) genotype, followed by the RST3 (OspC type I) genotype, causes greater inflammation and more severe disease, establishing a link between spirochetal virulence and host inflammation.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641395      PMCID: PMC3123987          DOI: 10.1016/j.ajpath.2011.02.018

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

Review 1.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

2.  Case definitions for public health surveillance.

Authors:  M Wharton; T L Chorba; R L Vogt; D L Morse; J W Buehler
Journal:  MMWR Recomm Rep       Date:  1990-10-19

3.  Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia.

Authors:  F Strle; R B Nadelman; J Cimperman; J Nowakowski; R N Picken; I Schwartz; V Maraspin; M E Aguero-Rosenfeld; S Varde; S Lotric-Furlan; G P Wormser
Journal:  Ann Intern Med       Date:  1999-01-05       Impact factor: 25.391

4.  Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.

Authors:  G Wang; C Ojaimi; R Iyer; V Saksenberg; S A McClain; G P Wormser; I Schwartz
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-08-11       Impact factor: 17.586

6.  Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors.

Authors:  J el Khoury; C A Thomas; J D Loike; S E Hickman; L Cao; S C Silverstein
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

7.  Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans.

Authors:  R R Müllegger; G McHugh; R Ruthazer; B Binder; H Kerl; A C Steere
Journal:  J Invest Dermatol       Date:  2000-12       Impact factor: 8.551

8.  Borrelia burgdorferi in joint fluid in chronic Lyme arthritis.

Authors:  D R Snydman; D P Schenkein; V P Berardi; C C Lastavica; K M Pariser
Journal:  Ann Intern Med       Date:  1986-06       Impact factor: 25.391

9.  The clinical evolution of Lyme arthritis.

Authors:  A C Steere; R T Schoen; E Taylor
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

10.  P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages.

Authors:  S E Hickman; J el Khoury; S Greenberg; I Schieren; S C Silverstein
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

View more
  46 in total

1.  Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with postinfectious, Borrelia burgdorferi-induced Lyme arthritis.

Authors:  Robert B Lochhead; Sheila L Arvikar; John M Aversa; Ruslan I Sadreyev; Klemen Strle; Allen C Steere
Journal:  Cell Microbiol       Date:  2018-10-17       Impact factor: 3.715

2.  Borrelia burgdorferi RevA Significantly Affects Pathogenicity and Host Response in the Mouse Model of Lyme Disease.

Authors:  Rebecca Byram; Robert A Gaultney; Angela M Floden; Christopher Hellekson; Brandee L Stone; Amy Bowman; Brian Stevenson; Barbara J B Johnson; Catherine A Brissette
Journal:  Infect Immun       Date:  2015-07-06       Impact factor: 3.441

3.  Correlation of Lyme Disease-Associated IgG4 Autoantibodies With Synovial Pathology in Antibiotic-Refractory Lyme Arthritis.

Authors:  Katherine B Sulka; Klemen Strle; Jameson T Crowley; Robert B Lochhead; Robert Anthony; Allen C Steere
Journal:  Arthritis Rheumatol       Date:  2018-09-24       Impact factor: 10.995

4.  Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis.

Authors:  Jameson T Crowley; Klemen Strle; Elise E Drouin; Annalisa Pianta; Sheila L Arvikar; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  J Autoimmun       Date:  2016-02-26       Impact factor: 7.094

Review 5.  Evolutionary aspects of emerging Lyme disease in Canada.

Authors:  N H Ogden; E J Feil; P A Leighton; L R Lindsay; G Margos; S Mechai; P Michel; T J Moriarty
Journal:  Appl Environ Microbiol       Date:  2015-08-21       Impact factor: 4.792

6.  Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis.

Authors:  Klemen Strle; Junghee J Shin; Lisa J Glickstein; Allen C Steere
Journal:  Arthritis Rheum       Date:  2012-05

7.  Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits.

Authors:  Elzbieta Jacek; Brian A Fallon; Abhishek Chandra; Mary K Crow; Gary P Wormser; Armin Alaedini
Journal:  J Neuroimmunol       Date:  2012-11-08       Impact factor: 3.478

Review 8.  Lyme disease ecology in a changing world: consensus, uncertainty and critical gaps for improving control.

Authors:  A Marm Kilpatrick; Andrew D M Dobson; Taal Levi; Daniel J Salkeld; Andrea Swei; Howard S Ginsberg; Anne Kjemtrup; Kerry A Padgett; Per M Jensen; Durland Fish; Nick H Ogden; Maria A Diuk-Wasser
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-06-05       Impact factor: 6.237

9.  Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis.

Authors:  Nalini K Vudattu; Klemen Strle; Allen C Steere; Elise E Drouin
Journal:  Arthritis Rheum       Date:  2013-06

10.  A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease.

Authors:  Elise E Drouin; Robert J Seward; Klemen Strle; Gail McHugh; Kianoosh Katchar; Diana Londoño; Chunxiang Yao; Catherine E Costello; Allen C Steere
Journal:  Arthritis Rheum       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.